Al-Ali HK et al. Efficacy and safety of fedratinib in patients with myelofibrosis and low baseline platelet counts in the phase 3 randomized FREEDOM2 trial. ASH 2024;Abstract 482.
Duan M et al. The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated myelofibrosis patients: The interim analysis of a prospective, open-label, multicenter, parallel-cohort, Phase 2 study. ASH 2024;Abstract 1002.
El Chaer F et al. Nuvisertinib (TP-3654), an investigational selective PIM2 kinase inhibitor, showed durable clinical response and sustained hematological improvement in patients with relapsed/refractory myelofibrosis. ASH 2024;Abstract 655.
Gangat N et al. A phase 1b study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia. ASH 2024;Abstract 657.
Harrison C et al. Hematological improvement and other clinical benefits of elritercept as monotherapy and in combination with myelofibrosis from the ongoing phase 2 RESTORE trial. ASH 2024;Abstract 997.
Masarova L et al. A Phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal responses to ruxolitinib. ASH 2024;Abstract 999.
Mascarenhas JO et al. Imetelstat versus best available therapy in patients with immediate-2 or high-risk myelofibrosis relapsed or refractory Janus kinase inhibitor in IMpactMF, a randomized, open-label, Phase 3 trial. ASH 2024;Abstract 1808.1.
Mascarenhas JO et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, Phase 3 study. ASH 2024;Abstract 3178.
Mascarenhas JO et al. Results from the randomized, multicenter, global phase 3 study BOREAS: Navtemadlin versus best available therapy in JAK inhibitor relapsed/refractory myelofibrosis. ASH 2024;Abstract 1000.
Mascarenhas J et al. Trial update from IMproveMF, an ongoing, open-label, dose-escalation and -expansion phase 1/1b trial to evaluate the safety, pharmacokinitics, and clinical activity of the novel combinations of imetelstat with ruxolitinib in patients with intermediate-1, intermediate-2, or high-risk myelofibrosis. ASH 2024;Abstract 998.
Vachhani P et al. Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications. ASH 2024;Abstract 4546.
Vachhani P et al. POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis who have a suboptimal response to ruxolitinib. ASH 2024;Abstract 1808.2.
Watts JM et al. Safety and efficacy of bromodomain and extra-terminal inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: A Phase 1 study. ASH 2024;Abstract 658.